Serrata Serrapeptase enteric-coated tablets 10mg №150

Serrata Serrapeptase enteric-coated tablets 10mg №150

Product Code: 7691
Availability: In Stock
$40.95USD
-+

Ask a question about this product

Composition

active substance:serratiopeptidase;

1 tablet contains 10 mg serratiopeptidase;

excipients:lactose, corn starch, magnesium carbonate, sodium starch (type A), magnesium stearate, coating Oradry-YS-1-7027*, coating Opadry-OU-P-7171**.

* -Opadry-YS-1-7027 Coating: hypromellose, titanium dioxide (E 171), triacetin.

**- coating Opadry-OU-P-7171: polyvinyl acetate phthalate, titanium dioxide (E 171), diethyl phthalate, stearic acid.

The

Dosage form

Tablet coated liner.

basic physico-chemical properties:circular biconvex tablets coated with a white intestinal-soluble coating.

The

drug description

Means used in the pathology of the musculoskeletal system. Enzymes. Code ATX M09A B.

The

Pharmacological properties

Pharmacodynamics.

Serratiopeptidase is a proteolytic enzyme isolated from the non-pathogenic intestinal bacteriumSerratia E15. It is characterized by fibrinolytic, anti-inflammatory and anti-edema activity. In addition to reducing the inflammatory process, serratiopeptidase reduces pain due to blocking the release of pain amines from inflamed tissue.

Serratiopeptidase binds in a ratio of 1: 1 with alpha 2-macroglobulin blood, masks its antigenicity, but retains its enzymatic activity. Then, gradually, in the place of inflammation, it passes into exudate and, accordingly, its blood level decreases.

Serratiopeptidase directly reduces dilation (expansion) of capillaries and controls their permeability due to hydrolysis of bradykinin, histamine and serotonin. Also serratiopeptidase locks inhibitors of plasmin, thus promoting fibrinolytic activity of plasmin. Due to proteolysis of structural proteins of sputum improves the rheological properties of the sputum and facilitates its expectoration.

the Enzymatic activity of the drug is 10 times higher than in ?-chymotrypsin. In the focus of chronic inflammation, serratopeptidase helps to reduce the level of mediators of inflammation of polypeptide nature (bradykinin), fibrin, but does not significantly affect the proteins of the living organism, such as albumin and ? - and ?-globulin.

the Drug penetrates well into inflammation, leasing necrotic tissues and their decay products, reduces hyperemia and accelerates the penetration and activity of antibiotics. The drug reduces the viscosity of saliva and nasal secretions, thereby facilitating their removal.

Pharmacokinetics.

the Drug passes through the stomach unchanged and is absorbed in the intestine. The drug is not inactivated by gastric juice. The maximum concentration in the blood plasma is reached after 1: 00. Serratiopeptidase reaches the bloodstream in the enzyme active form, is also excreted in the active form with bile and in small amounts is found in the urine.

Reading

Surgical conditions:sprains and ruptures of ligaments, fractures and dislocations, swelling caused by plastic surgery.

respiratory Diseases:reduces sputum viscosity and facilitates departure from the respiratory tract.

diseases of ENT organs:facilitates the discharge of the secret of the sinuses.

skin Diseases:acute inflammatory dermatoses.

diseases of the female genital organs and mammary glands:hematomas, stagnation in the mammary glands.

Contra

Hypersensitivity to serratiopeptidase or to any other component of the drug. Coagulation disorders.

Interaction with other medicinal products and other forms of interaction.

with simultaneous use of the drug increases the effect of anticoagulants (a combination of drugs should be used under medical supervision), accelerates the penetration of antibiotics and non-steroidal anti-inflammatory drugs into inflamed tissues.

application Features

Since the drug affects the blood clotting system, it should be used with caution in the following conditions:

The
    The
  • risk of bleeding
  • The
  • violation of the clotting time of blood
  • anticoagulant intake;
  • The
  • severe liver disease;
  • The
  • severe kidney disease.

Auxiliary substances.

the Drug contains lactose, so it should not be used in patients with rare hereditary diseases, such as galactose intolerance, Lapp lactase deficiency or malabsorption of glucose-galactose.

use during pregnancy or lactation.

the use of the drug during pregnancy and lactation is not recommended due to the lack of clinical data.

Ability to influence the reaction rate when driving motor transport or operating other mechanisms.

has No effect.

Method of application and doses

the Drug is prescribed to adults 1 tablet 2-3 times a day after meals.

the Tablets should be swallowed, without chewing, drinking 1 glass of water.

Maximum daily dose of 30 mg.

Dose and duration of treatment depend on the nature and dynamics of the pathological process and are determined in each case individually by the doctor.

Children.

the Drug should not be used in children due to lack of clinical data.

Overdose

Symptoms:nausea, vomiting, anorexia, epigastric discomfort, in some cases bleeding and blood veins in sputum.

Treatment.therapy is symptomatic.

Side effects

on the part of the digestive system:diarrhoea, nausea, vomiting, anorexia, epigastric discomfort, abdominal pain.

from the respiratory system:nosebleeds, sputum discharge mixed with blood, acute eosinophilic pneumonia. 

from the immune system:individuals with individual intolerance to the components of the drug may hypersensitivity reactions.

the skin isrash, itching, redness of the skin.

The

shelf Life

3 years.

storage Conditions

Store at a temperature not exceeding 25 ° C.

keep out of reach of children.

The

Packaging

№ 10: 10 tablets per strip; 1 strip in a carton box;

№ 10 ' 10: 10 tablets per strip; 1 strip per carton, 10 packs per carton

№ 103: 10 tablets per strip; 3 strips per carton;

No. 30 of 30 tablets in blister or strip, 1 blister or strip is in carton box;

No. 150: 30 tablets per strip; 5 strips in a carton pack.

The

Category vacation

According to the recipe.

The

Manufacturer

KUSUM LIKE A DRUG PVT LTD

KUSUM HEALTHCARE PVT LTD.

location of the manufacturer and address of the place of business

SP-289 (a), RIIKU Industrial area, Chopanki, Bhiwadi, get it. Alwar (Rajasthan), India.

SP-289 (a), RIICO Industrial area, Chopanki, Bhiwadi, Dist. Alwar (Rajasthan), India.

NEWMAXIMUM 1% SOLUTION of 1.5 ML n 5

Newmaximum 1% solution for injection is placed in ampoules of 1.5 ml, 5 pieces per pack. Assigned for short-term relief of the pain syndrome in patients with rheumatoid arthritis, ankylosing spondylitis, osteoarthritis. Also in situations where it is impossible to use other ways of drug administration (oral or rectal). Relates to non-steroidal anti-inflammatory drugs. After getting into the body has a pronounced antipyretic, anti-inflammatory, analgesic effect. 

How to use & nbsp;

Write a review

Note: HTML is not translated!
    Bad           Good

Recently viewed

Pharmacy03.com © 2019